Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

Name: Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
SKU: 2330
Price: 30.00 USD
Availability: InStock

$30.00

Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

By Larry Alphs, MD, PhD, John Panagides, PhD, and Scott Lancaster, MS

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Category: Medworks Reprint Series Tags: asenapine, clinical-trial, negative-symptoms, schizophrenia, study-design

Description

Description

Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

By Larry Alphs, MD, PhD, John Panagides, PhD, and Scott Lancaster, MS

PB-40-2-06-Alphs

Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

Description

Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia

Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Risperidone: Review of Its Therapeutic Utility in Depression

Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

Description

Related products

Ethical Issues in Schizophrenia: Considerations for Treatment and Research

Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia

Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Risperidone: Review of Its Therapeutic Utility in Depression